This appears to contradict previous studies that have indicated patients on drugs known as GLP-1 agonists need to stay on them to keep the weight off.
Epic says, however, its findings from nearly 40,000 patient records across 236 health systems are consistent with those previous studies - but it said the new research offers a more nuanced picture of patient outcomes. They also included patients prescribed the drugs for diabetes and not just weight loss.
[
add
]
[
|
|
...
]